Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It is
the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In …

Background: Hepatocellular carcinoma (HCC) has multiple prognostic factors, and there is
an increase in knowledge about the body composition and physical status of patients with …

Objective As the current therapeutic strategies for human hepatocellular carcinoma (HCC)
have been proven to have limited effectiveness, immunotherapy becomes a compelling way …

Hepatocellular carcinoma (HCC) is now the second leading cause of cancer-related deaths
globally and many patients have incurable disease. HCC predominantly occurs in the …

Despite the great success of chimeric antigen receptor T (CAR-T)–cell therapy in the
treatment of hematologic malignancies, CAR-T–cell therapy is limited in solid tumors …

Natural killer T (NKT) cells are innate-like lymphocytes that generally recognize lipid
antigens and are enriched in microvascular compartments of the liver. NKT cells can be …

The incidence of liver cancer is continuously rising where hepatocellular carcinoma (HCC)
remains the most common form of liver cancer accounting for approximately 80–90% of the …

Hepatocellular carcinoma (HCC) is the second most lethal cancer and a leading cause of
cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) significantly …

Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of
metabolic syndrome and has become the major cause of chronic liver disease, especially in …

Background & Aims The effect of hepatocellular carcinoma (HCC) on the response to
interferon-free direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C (CHC) …